The aberrant expression of FADD has been observed in multiple solid tumors, such as glioma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) (Chen et al. 2021; Han et al. 2020; Harari-Steinfeld et al. 2021). This evidence concerns the gene FADD and central nervous system cancer.